Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968218 | 0.89 | POLB (0.38) | POLBCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4969816 | 0.87 | ELANE (0.38) | POLBALDH1A1USP2LMNAGAA | |
| SCHEMBL4973353 | 0.80 | MEN1 (0.38) | POLBALDH1A1LMNAGAAMEN1 | |
| SCHEMBL4969646 | 0.78 | POLB (0.61) | POLBCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4970803 | 0.78 | ALOX12 (0.47) | POLBALDH1A1USP2LMNAMEN1 | |
| SCHEMBL4970662 | 0.76 | MEN1 (0.41) | POLBALDH1A1OPRL1LMNAMEN1 | |
| SCHEMBL10358621 | 0.76 | MEN1 (0.41) | POLBALDH1A1OPRL1LMNAMEN1 | |
| SCHEMBL10358622 | 0.75 | ALDH1A1 (0.36) | ALDH1A1LMNAGAAMEN1KMT2A | |
| SCHEMBL4968677 | 0.75 | MAPK1 (0.46) | POLBALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL4970655 | 0.73 | TSHR (0.40) | POLBALDH1A1OPRL1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | POLB 4733/4885CYP1A2 1140/4885CYP2C9 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.